Intravenous Hydrogen Therapy With Intracisternal Magnesium Sulfate Infusion in Severe Aneurysmal Subarachnoid Hemorrhage.
Satoru Takeuchi, Kosuke Kumagai, Terushige Toyooka, Naoki Otani, Kojiro Wada, Kentaro Mori · Stroke · 2021
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 37 patients with poor-grade subarachnoid hemorrhage, serum neuron-specific enolase levels were significantly lower in the Mg+H₂ group from days 3 to 14 than in the control group. These findings add human evidence supporting molecular hydrogen's therapeutic potential for stroke recovery.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 37 patients with poor-grade subarachnoid hemorrhage. Serum neuron-specific enolase levels were significantly lower in the Mg+H₂ group from days 3 to 14 than in the control group.
What the Researchers Studied
The researchers studied 37 patients with poor-grade subarachnoid hemorrhage. The study used a randomized human clinical trial. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Reported treatment duration: 14 days. Serum neuron-specific enolase levels were significantly lower in the Mg+H₂ group from days 3 to 14 than in the control group.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential for stroke recovery and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 37 patients with poor-grade subarachnoid hemorrhage. The reported sample size was 7. The study used a randomized human clinical trial. The reported treatment duration was 14 days.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.